Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.60 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.57 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8313343 | 0.85 | DPP4 (0.56) | DPP4DPP7DPP8GSK3BMEN1 | |
| SCHEMBL6638863 | 0.83 | DPP4 (0.53) | DPP4DPP7DPP8GSK3BMEN1 | |
| SCHEMBL651350 | 0.81 | DPP4 (0.54) | DPP4DPP7DPP8GSK3BMEN1 | |
| SCHEMBL21095681 | 0.81 | DPP4 (0.50) | DPP4DPP7DPP8GSK3BMEN1 | |
| SCHEMBL1514007 | 0.80 | DPP4 (0.53) | DPP4DPP7DPP8GSK3BMEN1 | |
| SCHEMBL5489225 | 0.80 | DPP4 (0.74) | DPP4DPP7DPP8 | |
| SCHEMBL6125342 | 0.79 | DPP4 (0.48) | DPP4DPP7DPP8GSK3BMEN1 | |
| SCHEMBL4445281 | 0.79 | DPP4 (0.53) | DPP4DPP7DPP8GSK3BMEN1 | |
| SCHEMBL14136370 | 0.78 | DPP7 (0.47) | DPP4DPP7DPP8MEN1KMT2A | |
| SCHEMBL21521629 | 0.78 | DPP7 (0.52) | DPP4DPP7DPP8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004071454-A2 | SUBSTITUTED AZETIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS INC. (US) | 2004-08-26 | — | — | WO | disclosed |